1,3-dipropyl-8-cyclopentylxanthine has been researched along with naloxone in 13 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (15.38) | 18.2507 |
| 2000's | 7 (53.85) | 29.6817 |
| 2010's | 4 (30.77) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bartoccini, F; Carminati, P; Castorina, M; Di Cesare, MA; Di Serio, S; Gallo, G; Ghirardi, O; Giorgi, F; Giorgi, L; Minetti, P; Piersanti, G; Tarzia, G; Tinti, MO | 1 |
| Attolini, M; Berthault, A; By, Y; Carrega, L; Chouraqui, G; Commeiras, L; Condo, J; Gaudel-Siri, A; Ghosh, N; Guieu, R; Mathew, SC; Parrain, JL; Rodriguez, J; Ruf, J; Virolleaud, MA | 1 |
| Coupar, IM; Hancock, DL | 1 |
| Naghipour, B; Roushan-zamir, F; Shafaghi, B; Zarrindast, MR | 1 |
| Dixon, AK; Freeman, TC; Lee, K; Preston, Z; Richardson, PJ; Widdowson, L | 1 |
| Christie, MJ; Hack, SP; Vaughan, CW | 1 |
| Cho, SK; Han, SM; Hwang, GS; Hwang, JH | 1 |
| Kato, M; Mobarakeh, JI; Nishino, S; Sakurada, S; Takahashi, K; Watanabe, H; Yanai, K | 1 |
| Antunes, C; Böhmer, AE; Elisabetsky, E; Lara, DR; Porciúncula, LO; Schallenberger, C; Schmidt, AP; Souza, DO | 1 |
| Martins, DF; Mazzardo-Martins, L; Piovezan, AP; Santos, AR; Soldi, F; Stramosk, J | 1 |
| Dal-Secco, D; Ludtke, DD; Martins, DF; Santos, ARS; Siteneski, A | 1 |
| Caumo, W; Dos Santos, ARS; Martins, DF; Martins, TC; Medeiros, LF; Nucci-Martins, C; Siteneski, A; Souza, A; Torres, ILS | 1 |
| Kumei, S; Nozu, T; Ohhira, M; Okumura, T | 1 |
13 other study(ies) available for 1,3-dipropyl-8-cyclopentylxanthine and naloxone
| Article | Year |
|---|---|
2-n-Butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization.
Topics: Adenine; Adenosine A2 Receptor Antagonists; Animals; Cell Line; Cricetinae; Cricetulus; Drug Design; Humans; Imidazoles; Male; Models, Molecular; Motor Activity; Purines; Radioligand Assay; Rats; Rats, Inbred F344; Structure-Activity Relationship; Triazoles | 2005 |
Design, synthesis and biological evaluation of a bivalent micro opiate and adenosine A1 receptor antagonist.
Topics: Adenosine; Adenosine A1 Receptor Antagonists; Anilides; Drug Design; Ligands; Molecular Structure; Receptors, Opioid, mu; Stereoisomerism; Structure-Activity Relationship | 2009 |
Studies investigating the possible involvement of adenosine in the antisecretory action of morphine.
Topics: Adenosine; Adenosine-5'-(N-ethylcarboxamide); Animals; Decerebrate State; Female; Intestinal Mucosa; Jejunum; Male; Morphine; Naloxone; Narcotic Antagonists; Norepinephrine; Purinergic P1 Receptor Agonists; Rats; Rats, Wistar; Reserpine; Sympatholytics; Vasoactive Intestinal Peptide; Xanthines | 1997 |
Effects of adenosine receptor agents on the expression of morphine withdrawal in mice.
Topics: Adenosine; Analysis of Variance; Animals; Behavior, Animal; Diarrhea; Male; Mice; Mice, Inbred Strains; Morphine; Morphine Dependence; Naloxone; Narcotic Antagonists; Narcotics; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Substance Withdrawal Syndrome; Theobromine; Xanthines | 1999 |
Adenosine receptor expression and function in rat striatal cholinergic interneurons.
Topics: Acetylcholine; Adenosine; Adenosine Deaminase; Animals; Baclofen; Bicuculline; Caffeine; Cholinergic Fibers; Corpus Striatum; Dose-Response Relationship, Drug; GABA Antagonists; Gene Expression; Male; Membrane Potentials; Naloxone; Narcotic Antagonists; Neurons; Phenethylamines; Rats; Rats, Sprague-Dawley; Receptors, Purinergic P1; RNA, Messenger; Tritium; Xanthines | 2000 |
Modulation of GABA release during morphine withdrawal in midbrain neurons in vitro.
Topics: Action Potentials; Adenosine; Affinity Labels; Animals; Colforsin; Cyclic AMP; Dipyridamole; Dose-Response Relationship, Drug; Drug Interactions; Enkephalins; Enzyme Inhibitors; gamma-Aminobutyric Acid; In Vitro Techniques; Isoquinolines; Male; Mesencephalon; Mice; Mice, Inbred C57BL; Morphine; Morphine Dependence; Naloxone; Narcotic Antagonists; Narcotics; Neural Inhibition; Neurons; Patch-Clamp Techniques; Periaqueductal Gray; Probenecid; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Substance Withdrawal Syndrome; Sulfonamides; Synaptic Transmission; Thioinosine; Time Factors; Uricosuric Agents; Vasodilator Agents; Xanthines | 2003 |
Morphine can enhance the antiallodynic effect of intrathecal R-PIA in rats with nerve ligation injury.
Topics: Adenosine A1 Receptor Agonists; Analgesics, Opioid; Animals; Circadian Rhythm; Dose-Response Relationship, Drug; Drug Synergism; Injections, Spinal; Ligation; Male; Morphine; Naloxone; Narcotic Antagonists; Pain; Pain Measurement; Peripheral Nervous System Diseases; Phenylisopropyladenosine; Rats; Rats, Sprague-Dawley; Xanthines | 2005 |
Enhanced antinociception by intracerebroventricularly and intrathecally-administered orexin A and B (hypocretin-1 and -2) in mice.
Topics: Analgesics; Animals; Gene Expression; Injections, Intraventricular; Injections, Spinal; Injections, Subcutaneous; Intracellular Signaling Peptides and Proteins; Male; Mice; Mice, Inbred C57BL; Naloxone; Narcotic Antagonists; Neuropeptides; Nociceptin; Opioid Peptides; Orexin Receptors; Orexins; Pain Measurement; Purinergic P1 Receptor Antagonists; Receptors, G-Protein-Coupled; Receptors, Neuropeptide; Theophylline; Xanthines | 2005 |
Anti-nociceptive properties of the xanthine oxidase inhibitor allopurinol in mice: role of A1 adenosine receptors.
Topics: Adenosine; Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Allopurinol; Analgesics; Animals; Capsaicin; Dose-Response Relationship, Drug; Glutamic Acid; Hot Temperature; Injections, Intraperitoneal; Male; Mice; Naloxone; Narcotic Antagonists; Pain; Pain Measurement; Pyrimidines; Triazoles; Uric Acid; Xanthine Oxidase; Xanthines | 2009 |
High-intensity swimming exercise reduces neuropathic pain in an animal model of complex regional pain syndrome type I: evidence for a role of the adenosinergic system.
Topics: Adenine; Adenosine; Adenosine A1 Receptor Antagonists; Adenosine A2 Receptor Antagonists; Adenosine Deaminase Inhibitors; Animals; Caffeine; Exercise Therapy; Hyperalgesia; Male; Mice; Naloxone; Narcotic Antagonists; Neuralgia; Neurons; Reflex Sympathetic Dystrophy; Swimming; Triazines; Triazoles; Xanthines | 2013 |
High-Intensity Swimming Exercise Decreases Glutamate-Induced Nociception by Activation of G-Protein-Coupled Receptors Inhibiting Phosphorylated Protein Kinase A.
Topics: Animals; Cyclic AMP-Dependent Protein Kinases; Glutamic Acid; Male; Mice; Naloxone; Neuralgia; Nociception; Pain Measurement; Phosphorylation; Physical Conditioning, Animal; Receptors, G-Protein-Coupled; Swimming; Xanthines | 2017 |
Neurobiological mechanisms of antiallodynic effect of transcranial direct current stimulation (tDCS) in a mice model of neuropathic pain.
Topics: Adenosine A1 Receptor Antagonists; Animals; Caffeine; Central Nervous System Stimulants; Disease Models, Animal; Dizocilpine Maleate; Excitatory Amino Acid Antagonists; Flumazenil; GABA Modulators; Hyperalgesia; Male; Mice; Morpholines; Naloxone; Narcotic Antagonists; Neuralgia; Pain Threshold; Physical Stimulation; Pyrazoles; Transcranial Direct Current Stimulation; Xanthines | 2018 |
Central oxytocin signaling mediates the central orexin-induced visceral antinociception through the opioid system in conscious rats.
Topics: Adenosine A1 Receptor Antagonists; Analgesics; Animals; Camphanes; Cannabinoid Receptor Agonists; Dopamine D2 Receptor Antagonists; Hormone Antagonists; Indoles; Male; Naloxone; Narcotic Antagonists; Nociception; Oxytocin; Piperazines; Rats; Rats, Sprague-Dawley; Receptors, Oxytocin; Reflex; Sulpiride; Xanthines | 2019 |